The website of Pathology In Practice Magazine

NEWS

R-Biopharm receives CTDA approval of COVID-19 test in the UK

R-Biopharm receives CTDA approval of COVID-19 test in the UK

R-Biopharm, an international specialist in clinical diagnostics, announces that the company’s RIDA®GENE Flu & SARS-CoV-2 multiplex test (PG6825) has been approved in the UK under the UK Health Security Agency’s Medical Devices CTDA Regulations 2021.

R-Biopharm will now work to resume the sale of the product in the UK. RIDA®GENE Flu & SARS-CoV-2 test is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of Flu A/Flu B and coronavirus (SARS-CoV-2) RNA in human nasal/throat swabs from persons with signs and symptoms of respiratory infection.

It is intended for professional use; for example, in hospital laboratories, reference laboratories, private laboratories, or public laboratories. The RIDA®GENE Flu & SARS-CoV-2 multiplex test targets the M gene/NP1 gene of the virus for Influenza A/B, and the E gene and RdRp gene in all currently known variants and mutations of the COVID-19 virus.

Only validated products, or products on the temporary protocol, can be sold in the UK after 31 October 2021. Jason Baggaley, Sales Manager of R-Biopharm for Great Britain, commented: “We are proud that our RIDA®GENE Flu & SARS-CoV-2 test was approved and added to the Coronavirus Test Device Approvals (CTDA) register, and our customers will continue to be able to distinguish between the flu and an infection with the coronavirus.

https://r-biopharm.com/

FEATURES

Beyond LIS and LIMS: coordinated orders and results management

Extending laboratory reach beyond the hospital works best with the integration of specialised surrounding solutions. Here, in a moderated session, thought-leaders from Sunquest and CliniSys Group explore the benefits of purpose-built technology.

Do we need another crisis before changing how biosamples are shared?

What is a crisis? According to dictionary definitions it is a time of great difficulty or danger when problems must be solved or important decisions must be made. Here, Robert Hewitt looks specifically at crises affecting biosample sharing.

Near-patient testing in microbiology: experiences/future prospects

A look back at the last BSMT Annual Scientific Conference on COVID-19 and in particular at one of the consequences of the pandemic – the increased demand for near-patient testing.

Higher-specificity D-dimer scores in health technology assessment

Recent studies have supported a D-dimer assay role in ruling out venous thromboembolism and pulmonary embolism, linking it to health technology assessment savings, as Gillian Eyre explains.

PRODUCTS

LATEST ISSUEs

December 2021
January 2021
September 2020

Upcoming Events

IBMS Biomedical Science Congress 2022

International Convention Centre, Birmingham
14-17 March 2022

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

IBMS Biomedical Science Congress 2022

International Convention Centre, Birmingham
14-17 March 2022

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2021 Step Communications Ltd. Registered in England. Registration Number 3893025